APAlex Philippidis
Alex Philippidis
*This is an algorithmically generated author record based on publicly available information.
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Latest Publications
- 16 June 2023
- Published by SAGE Publications in Human Gene Therapy
- Vol. 34 (11-12) , 477-480
Food and Drug Administration Sets Stage for Approval of First Duchenne Muscular Dystrophy Gene Therapy
- 16 June 2023
- Published by SAGE Publications in Human Gene Therapy
- Vol. 34 (11-12) , 477-480
Food and Drug Administration Sets Stage for Approval of First Duchenne Muscular Dystrophy Gene Therapy
- 17 May 2023
- Published by SAGE Publications in Human Gene Therapy
- Vol. 34 (9-10) , 341-344
CRISPR Therapeutics, Vertex Complete Rolling Biologics License Applications for Exa-Cel in Sickle Cell Disease, Beta Thalassemia
- 17 May 2023
- Published by SAGE Publications in Human Gene Therapy
- Vol. 34 (9-10) , 341-344
CRISPR Therapeutics, Vertex Complete Rolling Biologics License Applications for Exa-Cel in Sickle Cell Disease, Beta Thalassemia
- 17 April 2023
- Published by SAGE Publications in Human Gene Therapy
- Vol. 34 (7-8) , 255-258
PASTE, Don't Cut: Genome Editing Tool Looks Beyond CRISPR and Prime
- 17 April 2023
- Published by SAGE Publications in Human Gene Therapy
- Vol. 34 (7-8) , 255-258
PASTE, Don't Cut: Genome Editing Tool Looks Beyond CRISPR and Prime
- 20 March 2023
- Published by SAGE Publications in Human Gene Therapy
- Vol. 34 (5-6) , 177-179
Magenta Halts Development, Pursues Strategic Alternatives After Patient Death
- 20 March 2023
- Published by SAGE Publications in Human Gene Therapy
- Vol. 34 (5-6) , 177-179
Magenta Halts Development, Pursues Strategic Alternatives After Patient Death
- 1 February 2023
- Published by SAGE Publications in Human Gene Therapy
- Vol. 34 (3-4) , 90-93
Graphite Bio Pauses Lead Gene Editing Program in Sickle Cell Disease
- 1 February 2023
- Published by SAGE Publications in Human Gene Therapy
- Vol. 34 (3-4) , 90-93
Graphite Bio Pauses Lead Gene Editing Program in Sickle Cell Disease
- 17 January 2023
- Published by SAGE Publications in Human Gene Therapy
- Vol. 34 (1-2) , 4-7
Fyodor Urnov Articulates New Model for Developing, Financing Therapies
- 17 January 2023
- Published by SAGE Publications in Human Gene Therapy
- Vol. 34 (1-2) , 4-7
Fyodor Urnov Articulates New Model for Developing, Financing Therapies
- 14 December 2022
- Published by SAGE Publications in Human Gene Therapy
- Vol. 33 (23-24) , 1224-1227
Brother of Cure Rare Disease CEO Dies in Trial of Duchenne Muscular Dystrophy Therapy
- 14 December 2022
- Published by SAGE Publications in Human Gene Therapy
- Vol. 33 (23-24) , 1224-1227
Brother of Cure Rare Disease CEO Dies in Trial of Duchenne Muscular Dystrophy Therapy
- 1 December 2022
- Published by SAGE Publications
- Vol. 1 (6) , 472-475
Made in Britain: Venture Fund Boosts Synthetic Biology
- 1 December 2022
- Published by SAGE Publications
- Vol. 1 (6) , 472-475
Made in Britain: Venture Fund Boosts Synthetic Biology
- 1 October 2022
- Published by SAGE Publications in Human Gene Therapy
- Vol. 33 (19-20) , 1006-1009
Akouos, Immusoft Win FDA Clearances for First-of-Their-Kind Gene Therapies
- 1 October 2022
- Published by SAGE Publications in Human Gene Therapy
- Vol. 33 (19-20) , 1006-1009
Akouos, Immusoft Win FDA Clearances for First-of-Their-Kind Gene Therapies
- 1 October 2022
- Published by SAGE Publications
- Vol. 1 (5) , 411-414
Engineerable Biology: Generate Biomedicines Builds Pipeline, Expands Modalities
- 1 October 2022
- Published by SAGE Publications
- Vol. 1 (5) , 411-414
Engineerable Biology: Generate Biomedicines Builds Pipeline, Expands Modalities